Bose, P., McCue, D., Wurster, S., Wiederhold, N. P., Kadia, T. M., Borthakur, G., . . . Kontoyiannis, D. P. (2019). 2121. Isavuconazole (ISAV) as Primary Anti-Fungal Prophylaxis (PAP) in Patients with Acute Myeloid Leukemia (AML) or Myelodysplastic Syndrome (MDS): An Open-Label, Prospective Study. Open Forum Infect Dis.
Citação norma ChicagoBose, Prithviraj, et al. "2121. Isavuconazole (ISAV) As Primary Anti-Fungal Prophylaxis (PAP) in Patients With Acute Myeloid Leukemia (AML) or Myelodysplastic Syndrome (MDS): An Open-Label, Prospective Study." Open Forum Infect Dis 2019.
Citação norma MLABose, Prithviraj, et al. "2121. Isavuconazole (ISAV) As Primary Anti-Fungal Prophylaxis (PAP) in Patients With Acute Myeloid Leukemia (AML) or Myelodysplastic Syndrome (MDS): An Open-Label, Prospective Study." Open Forum Infect Dis 2019.